GET DAILY SIGNALSNKTX Stock: Can Nkarta Reach the $11 Target for +590% Upside?
Key Takeaways
- The central price target in this analysis is $11, the arithmetic mean of five verified, current analyst price targets.
- The latest verified closing price sits near $1.59, so the target implies a move of roughly 590% — a substantial required gain.
- Individual analyst targets range from a low of $9 (Evercore ISI) to a high of $14 (H.C. Wainwright), and all covering firms rate the stock a Buy.
- The strongest supports are encouraging early clinical data for NKX019 and a clean safety profile; the biggest risks are clinical-stage losses, dilution, and small, short-duration trial data.
- The stock traded near its 52-week low in early November 2026 despite positive data, reflecting investor caution about durability and path to market.
- For additional context, explore the Major News, Today's Price Move, Forecast, and Earnings pages for NKTX.
- You can also explore Trending AI Robots to see AI-driven tools monitoring stocks and ETFs in real time.
Reviewing the Current Analyst Price Targets
This analysis reviews five individually attributable, current analyst price targets for NKTX: Needham at $11, Stifel Nicolaus (Stephen Willey) at $10, H.C. Wainwright (Emily Bodnar) at $14, Mizuho at $12, and Evercore ISI at $9, which was cut from $25 in May 2026. Their arithmetic mean is $11.20, rounded to a clean central target of $11. The low-to-high range is wide, from $9 to $14, signaling meaningful disagreement about the durability and commercial value of the data. Notably, Evercore ISI's reduction from $25 to $9 reflects a sharp reassessment of the pipeline. Additional firms cover the stock with Buy ratings but no published target, including TD Cowen, while William Blair initiated coverage with a Hold in September 2026. This target is a calculated average of the collected targets, not an official published consensus. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Where NKTX Stands Today and the Road Ahead
As of early November 2026, NKTX closed near $1.59, down from a 52-week high of $3.72 and well below its 50-day ($2.34) and 200-day ($2.52) moving averages. Reaching the $11 central target would require a gain of roughly 590%, an extremely large move for a single research horizon and one that effectively assumes successful clinical development and a pathway toward commercialization. The company reported a third-quarter 2026 GAAP loss of $0.45 per share and had about $216 million in cash, cash equivalents, and investments as of September 30, 2026. Nkarta has also pivoted its strategy, discontinuing NKX019 development in relapsed/refractory non-Hodgkin lymphoma to focus on autoimmune indications.
Factors That Could Drive NKTX Higher
The clearest support is the initial clinical data for NKX019 presented at the American College of Rheumatology (ACR) Convergence 2026. In myositis, five of six patients (83%) treated at the 4 billion-cell dose achieved moderate or major responses by Total Improvement Score; in systemic sclerosis, six of seven (86%) achieved an rCRISS-25 response or better. Across 40 patients, the company reported no cytokine release syndrome (CRS), no neurotoxicity, and no graft-versus-host disease, supporting an outpatient-friendly profile. An off-the-shelf, allogeneic CAR-NK platform could also offer a cost and logistics advantage over autologous CAR-T therapies if it advances further. All covering analysts currently rate the stock a Buy, and the shares trade well below book value, at roughly 0.5 times price-to-book.
Key Risks Standing in the Way
The principal obstacle is that NKTX is still clinical-stage, with no revenue and widening net losses of about $129 million over the trailing twelve months. The autoimmune data, while encouraging, come from small patient numbers with limited follow-up, and the company itself describes the findings as preliminary. The share-price decline of roughly 29% intraday on November 9, 2026 — despite the positive readout — suggests investors are skeptical that responses will prove durable or sufficient for registration. Dilution risk remains, as continued trials and potential commercialization will likely require additional capital beyond the current cash balance, and competition in the CD19-directed autoimmune cell therapy space is intensifying.
Technical Analysis and Support Levels
The stock's 52-week range of roughly $1.13 to $3.72 frames the relevant technical structure. The $1.13 area represents the primary support level, tested intraday in early November 2026. Below that, support is sparse. On the upside, the first meaningful resistance sits near the prior consolidation zone around $2.00 to $2.60, followed by the 52-week high near $3.72. With the price trading below both major moving averages, the longer-term trend remains clearly negative, meaning any path toward the $11 target would first require a sustained reversal and a decisive break above those overhead levels.
What to Watch in the Coming Months
Analyst price targets typically reflect a research horizon of about 12 months, though individual firms may differ. Investors should watch the durability of NKX019 responses as follow-up data mature, enrollment and dose-escalation updates across the Ntrust program, and any regulatory or partnership developments. Cash runway and the timing of any future financing are also critical, as are quarterly earnings reports — including EPS (earnings per share) results — and analyst target revisions, which have been volatile, as evidenced by Evercore ISI's sharp cut. These milestones, rather than any single data point, will determine whether the gap between the current price and the $11 target narrows.
AI Daily Buy/Sell Signals
In my own work tracking volatile clinical-stage names, I often turn to Tickeron’s AI Daily Buy/Sell Signals to monitor momentum shifts and technical behavior across thousands of stocks and ETFs. The tool generates Buy, Sell, or Hold signals based on changing market conditions and AI-driven analysis. For a high-volatility, data-driven name like NKTX, these signals can help identify shifts in momentum, monitor positions, and spot changing trends more efficiently than manual review alone. Traders can use the platform to discover opportunities and stay ahead of rapid moves in the biotechnology sector.
My Overall Take
Whether NKTX can reach the $11 central target depends on factors that lie largely in the future: durable clinical responses, successful advancement through later-stage trials, and sufficient financing. The target, a rounded average of five analyst price targets ranging from $9 to $14, implies a very large move of roughly 590% from the current price near $1.59. The bullish case rests on promising early NKX019 efficacy and a clean safety profile; the bearish case points to clinical-stage losses, small and preliminary datasets, dilution risk, and a market that sold the stock down even after positive data. Given the wide analyst range and the early nature of the data, the $11 target should be read as a long-shot, high-upside scenario rather than a near-term expectation, and investors should monitor the durability data, cash runway, and analyst revisions before drawing conclusions. From what I see, one thing that stands out is how quickly sentiment can shift even on encouraging readouts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
NKTX sees its 50-day moving average cross bearishly below its 200-day moving average
The 50-day moving average for NKTX moved below the 200-day moving average on October 21, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day moving average for NKTX crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NKTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for NKTX entered a downward trend on November 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where NKTX's RSI Oscillator exited the oversold zone, 35 of 40 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 66 cases where NKTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Moving Average Convergence Divergence (MACD) for NKTX just turned positive on November 04, 2026. Looking at past instances where NKTX's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
Following a +13.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where NKTX advanced for three days, in 208 of 247 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
NKTX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.500) is normal, around the industry mean (3.498). P/E Ratio (-1.088) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. NKTX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NKTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
Will Ripple Make a Superior Payment System?
What is the Federal Supplemental Education Opportunity Grant?
What is a Foreign Portfolio Investment (FPI)?
What is the U.S. Dollar Index (USDX) and How Does It Impact Global Finance?
Palantir Technologies (PLTR) Soars on Strategic AI Partnerships and Robust Q1 Performance
General Information
a biopharmaceutical company, which engages in the discovery, development, and commercialization of natural killer cell therapies for the treatment of cancer
Industry Biotechnology
Advertisement